Study Illuminates Link Between Pretransplant Patient-Reported Outcomes and Post-HCT Complications | Cancer Nursing Today
Research presented at ASH 2024 showed baseline fatigue and depression were associated with acute graft-versus-host-disease.
Related Articles
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る by The Uromigos
3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！
Updates from the STEP-HFpEF Trial | ESC 2024
Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Mikhail Kosiborod, MD, FACC discuss an exciting secondary analysis of the STEP-HFpEF program, sheddin…
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials
AbstractBackgroundMore women than men have heart failure with preserved ejection fraction (HFpEF).ObjectivesThe purpose of this study was to assess baseline characteristics and treatment effect of…
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program
AbstractBackgroundObesity is a key factor in the development and progression of both heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF). In the…
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure:
AbstractBackgroundObesity is associated with adverse cardiac remodeling and is a key driver for the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg)…
Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program
AbstractBackgroundInflammation is thought to be an important mechanism for the development and progression of obesity-related heart failure with preserved ejection fraction (HFpEF). In the STEP-HFp…
Semaglutide and NTproBNP in Obesity-Related HFpEF: Insights from STEP-HFpEF Program:
AbstractBackgroundThe glucagon-like peptide-1 receptor agonist, semaglutide, improved health status and reduced body weight in patients with obesity-related heart failure (HF) with preserved ejecti…
What Is the Difference in Ide-Cel Efficacy, Toxicity Between Age Groups of Patients With MM? | Blood Cancers Today
Ide-cel demonstrated similar outcomes and toxicities among patients aged 70 years and older compared with younger patients.
RBC Transfusion Dependency Linked to Reduced Overall Survival in Higher-Risk MDS | Docwire News
Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.
Episode 379: Uromigos Japan: 2024年のGU Oncologyを振り返る by The Uromigos
3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！